. Author manuscript; available in PMC: 2022 Sep 27.

Published in final edited form as: Mod Pathol. 2022 Jun 25:10.1038/s41379-022-01102-x. doi: 10.1038/s41379-022-01102-x

Table 3. Agreement between p53 immunohistochemistry and TP53 NGS analysis.

p53 IHC	(Likely) pathogenic mutation on TP53 NGS analysis
	All EC		POLE wildtype and MMR proficient EC
	Absent	Present	Absent	Present
Wildtype	215	19	96	4
Abnormal	13	97	6	76
Total	228	116	102	80
Accuracy	90.7% (95% CI 87.6-93.8%)		94.5% (95% CI 89.4-99.6%)
Sensitivity	83.6% (95% CI 79.7-87.5%)		95.0% (95% CI 90.2-99.8%)
Specificity	94.3% (95% CI 91.8-96.7%)		94.1% (95% CI 88.9-99.3%)

Abbreviations: IHC, immunohistochemistry; NGS, next generation sequencing; EC, endometrial cancer; MMR, mismatch repair; CI, confidence interval

In bold, EC with concordant p53 IHC and sequencing for TP53 mutations